Lipoprotein-antibody autoimmune complexes and their role in atherogenesis

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The autoimmune lipoprotein-antibody complex was isolated from the blood and the vessel wall of man and their high atherogenecity was shown to be mainly due to its citotoxicity and the ability to induce forma­tion of foam cells. However, antilipoprotein antibody suppressed the uptake of modified lipoproteins by macrophages.

It was shown that lipoprotein-antibody immune complexes were very quickly eliminated from circulation probably due to active uptake by cells of the reticuloendothelial system.

A suggestion is put forward that formation of lipoprotein-antibody complexes is likely to be regarded as the immune response to the appearence of highly atherogenic oxidized lipoproteins to decrease athero­genecity of these lipoproteins and to eliminate them from organism as quickly as possible.

About the authors

A. D. Denisenko

Research Institute of Experimental Medicine of the RAMS

Author for correspondence.
Email: shabanov@mail.rcom.ru
Russian Federation, Saint Petersburg

References

  1. Нагорнев В. А., Восканъянц А. Н. Атерогенез как иммуновоспалительный процесс // Вестник РАМН. 2004. № 7. С. 3-11.
  2. Hansson G. К. Immune and inflammatory mechanisms in the development of atherosclerosis // Br. Heart J. 1993. Vol. 69 (Suppl. 1). P. 38-41.
  3. Libby P, Hansson G. K. Involvement of the immune system in human atherogenesis: Current knowledge and un-answered question // Lab. Invest. 1991. Vol. 64. P. 5-15.
  4. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime //Nat. Med. 2002. Vol. 8. P. 1211-1217.
  5. Климов A. H, Денисенко А. Д. О роли иммунных комплексов липопротеид-антитело в атерогенезе // Успехи совр. биол. 1988. Т. 196. № 2 (5). С. 279-289.
  6. Klimov A. N., Denisenko A. D., PopovA. V. et al. Lipoprotein-antibody immune complexes. Their catabolism and role in foam cell formation // Atherosclerosis. 1985. Vol. 58. P. 1-15.
  7. Lopes-Virella M. E, Virella G., Orchard T. J. et al. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus // Clin. Immunol. 1999. Vol. 90. P. 165-172.
  8. Денисенко А. Д., Виноградов А. Г, Нагорнев В. А. и др. Взаимодействие макрофагов с аутоиммунным комплексом липопротеид- антитело // Иммунол. 1989. № 2. С. 32-35.
  9. Klimov A. N., Denisenko A. D., Vinogradov A. G. et al. Accumulation of cholesteryl esters in macrophages incubated with human lipoproteinantibody autoimmune complex // Atherosclerosis. 1988. Vol. 74. P. 41-46.
  10. Иоффе В. И, Зубжицкий Ю. Н., Нагор- нев В. А., Климов А. Н. К иммунологической характеристике экспериментального атеросклероза // Бюл. экспер. биол. 1973. № 6. С. 72-76.
  11. Каленич О. С., Тертое В. В., Новиков И. Д. и др. Холестерин циркулирующих иммунных комплексов как биологический маркер коронарного атеросклероза // Кардиол. 1991. Т. 31. № 2. С. 42-44.
  12. Denisenko A. D., Makovejchuk Е. G., Vinogradov A. G. et al. Autoantibodies against oxidized low density lipoproteins and lipoprotein-antibody autoimmune complexes in human atherosclerosis // Eur. J. Lab. Med. 1996. Vol. 4. P. 85-90.
  13. Salonen J. T, Yla-Herttuala S., Yamamoto R. et al. Autoantibody against oxidized LDL and progression of carotid atherosclerosis // Lancet. 1992. Vol. 339. P. 883-887.
  14. Zhou X., Caligiuri G., Hamsten A. et al. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis //Arterioscler. Thromb. Vase. Biol. 2001. Vol. 21. P. 108-114.
  15. Fredrikson G. N., Syderberg L, Lindholm M. et al. Inhibition of Atherosclerosis in ApoE-Null Mice by Immunization with ApoB-100 Peptide Sequences // Arterioscler. Thromb. Vase. Biol. 2003. Vol. 23. P. 879-884.
  16. Sakata N, Imanaga Y, Meng J., Tachikawa Y, Takebayashi S., Nagai R., Horiuchi S., Itabe H, Takano T Immunohistochemical localization of different epitopes of advanced glycation end products in human atherosclerotic lesions // Atherosclerosis. 1998. Vol. 141. P. 61-75.
  17. Yla-Herttuala S., Palinski W., Rosenfeld M. E., Parthasarathy S., Carew T E., Butler S., Witz- tum J. L., Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man // J. Clin. Invest. 1989. Vol. 84. P. 1086-1095.
  18. Нагорнев В. А., Восканяну A. H, Виноградов А. Г. и др. Цитотоксический эффект липопротеинов низкой плотности // Бюл. экспер. биол. мед. 2003. Т. 13 5. № 1. С. 107-109.
  19. Климов А. Н, Денисенко А. Д, Нагорнев В. А. Иммунные комплексы липопротеид-антитело // Иммунореактивность и атеросклероз / Ред. А. Н. Климов. Л.: Медицина, 1986. С.107-128.
  20. Brown М. A vaccine against atherosclerosis // Drug Discuvery Today. 2002. Vol. 7. P. 588-590.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2007 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.